Compare AOMR & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AOMR | ACIU |
|---|---|---|
| Founded | 2018 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 210.5M | 244.3M |
| IPO Year | 2019 | 2015 |
| Metric | AOMR | ACIU |
|---|---|---|
| Price | $8.91 | $2.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $11.08 | $10.00 |
| AVG Volume (30 Days) | 151.5K | ★ 298.1K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | ★ 14.18% | N/A |
| EPS Growth | ★ 53.85 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $706.75 |
| Revenue Next Year | $1.38 | $321.13 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.96 | $1.65 |
| 52 Week High | $10.14 | $4.00 |
| Indicator | AOMR | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 64.94 | 51.75 |
| Support Level | $8.73 | N/A |
| Resistance Level | $9.33 | $3.20 |
| Average True Range (ATR) | 0.23 | 0.12 |
| MACD | 0.08 | 0.04 |
| Stochastic Oscillator | 100.00 | 86.54 |
Angel Oak Mortgage REIT Inc is a real estate finance company focused on acquiring and investing in first and second lien non-QM loans and other mortgage-related assets in the U.S. mortgage market. Its objective is to generate attractive risk-adjusted returns for its stockholders, through cash distributions and capital appreciation, across interest rate and credit cycles. The company operates in a single operating segment, which is to acquire, invest in, and finance mortgage-related assets.
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.